Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome : a pilot randomized clinical trial
Articolo
Data di Pubblicazione:
2018
Citazione:
Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome : a pilot randomized clinical trial / C. Cremon, S. Guglielmetti, G. Gargari, V. Taverniti, A.M. Castellazzi, C. Valsecchi, C. Tagliacarne, W. Fiore, M. Bellini, L. Bertani, D. Gambaccini, M. Cicala, B. Germanà, M. Vecchi, I. Pagano, M.R. Barbaro, L. Bellacosa, V. Stanghellini, G. Barbara. - In: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL. - ISSN 2050-6406. - 6:4(2018 May), pp. 604-613.
Abstract:
Background: Evidence suggests a role of intestinal microbiota-host interactions in the pathophysiology and symptoms of irritable bowel syndrome (IBS). Objective: The objective of this article is to assess the effects of Lactobacillus paracasei CNCM I-1572 on clinical and gut microbiota-related factors in IBS. Methods: We conducted a multicenter, randomized, double-blind, cross-over, 18-week, placebo-controlled, pilot trial assessing the effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota composition, fecal short chain fatty acid (SCFA), immunoglobulin A, and cytokines in IBS. The intestinal microbial ecosystem was characterized by 16S rRNA gene profiling. Results: Forty IBS patients were enrolled from five Italian centers. Lactobacillus paracasei CNCM I-1572 did not significantly improve IBS symptoms, including primary efficacy variables worst abdominal pain/discomfort and IBS degree of relief. Interestingly, Lactobacillus paracasei CNCM I-1572 induced a significant reduction in genus Ruminococcus, dominated by taxa related to Ruminococcus bromii and Ruminococcus callidus, a significant increase in the SCFAs acetate and butyrate, and a significant reduction in the pro-inflammatory cytokine interleukin-15. Conclusions: This pilot study shows that Lactobacillus paracasei CNCM I-1572 is able to modulate gut microbiota structure/function and reduce immune activation in IBS. As no statistically significant effect on IBS-symptoms was found, further studies are necessary to determine the role of this probiotic in IBS. The study was registered at ClinicalTrials.gov registry under identifier NCT02371499.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
dietary compounds; Irritable bowel syndrome; microbiota; probiotics; Oncology; Gastroenterology
Elenco autori:
C. Cremon, S. Guglielmetti, G. Gargari, V. Taverniti, A.M. Castellazzi, C. Valsecchi, C. Tagliacarne, W. Fiore, M. Bellini, L. Bertani, D. Gambaccini, M. Cicala, B. Germanà, M. Vecchi, I. Pagano, M.R. Barbaro, L. Bellacosa, V. Stanghellini, G. Barbara
Link alla scheda completa: